Tesaglitazar, a dual PPAR-α/γ agonist, hamster carcinogenicity, investigative animal and clinical studies.
about
Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer TherapeuticsPeroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside.Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models.Nuclear receptors as pharmaceutical targets: rise of FXR and rebirth of PPAR?Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic.
P2860
Tesaglitazar, a dual PPAR-α/γ agonist, hamster carcinogenicity, investigative animal and clinical studies.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Tesaglitazar, a dual PPAR-α/γ ...... e animal and clinical studies.
@en
Tesaglitazar, a dual PPAR-α/γ ...... e animal and clinical studies.
@nl
type
label
Tesaglitazar, a dual PPAR-α/γ ...... e animal and clinical studies.
@en
Tesaglitazar, a dual PPAR-α/γ ...... e animal and clinical studies.
@nl
prefLabel
Tesaglitazar, a dual PPAR-α/γ ...... e animal and clinical studies.
@en
Tesaglitazar, a dual PPAR-α/γ ...... e animal and clinical studies.
@nl
P2093
P2860
P356
P1476
Tesaglitazar, a dual PPAR-α/γ ...... e animal and clinical studies.
@en
P2093
Anna-Lena Berg
Bo Blomgren
Hanna Lundgren
Heike Hellmold
Inger Skånberg
John Evans
Jonathan Tugwood
Maritha Marcusson-Ståhl
Niclas Sjögren
P2860
P356
10.1177/0192623311429972
P407
P577
2011-11-30T00:00:00Z